Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 20;5(6):524.
doi: 10.1002/iju5.12538. eCollection 2022 Nov.

Editorial Comment to A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab

Takeshi Yuasa  1
Affiliations
Editorial

Editorial Comment to A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab

Takeshi Yuasa. IJU Case Rep. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declare no conflict of interest.

Similar articles

See all similar articles

References

    1. Postow MA, Sidlow R, Hellmann MD. Immune‐related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 2018; 378: 158–68. - PubMed
    1. Yuasa T, Urasaki T, Oki R. Recent advances in medical therapy for urological cancers. Front. Oncol. 2022; 12: 746922. - PMC - PubMed
    1. Fujiwara R, Kageyama S, Yuasa T. Developments in personalized therapy for metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 2022; 22: 647–55. - PubMed
    1. Fukunaga H, Sumii K, Kawamura S, Okuno M, Taguchi I, Kawabata G. A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab IJU Case Rep. 2022; 5: 521–3. - PMC - PubMed
    1. Ramos‐Casals M, Brahmer JR, Callahan MK et al. Immune‐related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Primers. 2020; 6: 38. - PMC - PubMed

Publication types